title: The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
abstract: Excision repair cross-complementation group 1 (ERCC1) protein has been extensively investigated as a prognostic and predictive factor for platinum-based treatment in head and neck squamous cell carcinoma (HNSCC) but with inconsistent results. We performed the present meta-analysis to better elucidate this issue in advanced HNSCC. A literature search was conducted using the PubMed and Web of Science databases. The inclusion criteria were head and neck cancer patients with platinum-based treatment and evaluation of the correlation between ERCC1 expression and clinical outcomes [objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), both unadjusted and adjusted estimates]. In high vs. low pooled analyses, high ERCC1 expression was associated with unfavorable OS [hazard ratio (HR) = 1.95, 95 % confidence interval (CI) 1.18-3.21, p = 0.009], PFS (HR = 2.39, 95 % CI 1.74-3.28, p = 0.000) and ORR (odds ratio = 0.48, 95 % CI 0.23-0.98, p = 0.044). In the subgroup analysis of adjusted OS estimates, ERCC1 was a predictor of shorter survival in Asians (HR = 3.13, 95 % CI 2.09-4.70, p = 0.000) and Caucasians (HR = 2.02, 95 % CI 1.32-3.07, p = 0.001) but of longer survival in South Americans (HR = 0.17, 95 % CI 0.07-0.40, p = 0.000). Immunohistochemistry proved to be of predictive value irrespective of used antibody (p = 0.009). In the stratified analysis according to the tumor site, ERCC1 expression was associated with OS in nasopharyngeal cancer (HR = 2.72, 95 % CI 1.79-4.13, p = 0.000). ERCC1 has a potential to become predictive and prognostic factor enabling treatment tailoring in HNSCC patients.
authors.affiliation: Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia. vesna.bisof@zg.t-com.hr.|School of Medicine, University of Osijek, Osijek, Croatia. vesna.bisof@zg.t-com.hr.
authors.forename: Vesna
authors.initials: V
authors.lastname: Bišof
authors.affiliation: Institute for Anthropological Research, Ljudevita Gaja 32, Zagreb, Croatia.
authors.forename: Matea
authors.initials: M
authors.lastname: Zajc Petranović
authors.affiliation: Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia.
authors.forename: Zoran
authors.initials: Z
authors.lastname: Rakušić
authors.affiliation: Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia.
authors.forename: Kristina Ruža
authors.initials: KR
authors.lastname: Samardžić
authors.affiliation: Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb, Croatia.|School of Medicine, University of Zagreb, Zagreb, Croatia.
authors.forename: Antonio
authors.initials: A
authors.lastname: Juretić
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000378:metabolism*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D017671:Platinum Compounds / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D017671:Platinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases
keywords: Chemoradiotherapy; ERCC1; HNSCC; Meta-analysis; Platinum-based chemotherapy